36th Annual Meeting • Nov. 12–14, 2021

The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021) provides a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.

The Annual Meeting consists of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting includes updates on major national and international initiatives coming from academia, government and industry, as well as important society projects.

36th Annual Meeting Organizers

  • Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine

  • Paolo A. Ascierto, MD – Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

  • Margaret K. Callahan, MD, PhD – Memorial Sloan Kettering Cancer Center

  • Michelle Rohlfs, APRN, FNP-BC, AOCNP – The University of Texas MD Anderson Cancer Center

Annual Program Committee

  • Chair: Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

  • Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center

  • Lorenzo Falchi, MD – Memorial Sloan Kettering Cancer Center

  • Brianna Hoffner, MSN, ANP-BC, AOCNP – Harborside 

  • Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

Target Audience

The audience includes basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers, who wish to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment.

Learning Objectives

Upon conclusion of this activity, participants should be able to:

  • Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research

  • Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy

  • Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic intervention

    Continuing Education

    This program will be accredited to offer CME, CNE, CPE and MOC credits. 

    SITC's 36th Annual Meeting is supported in part by grants from 7 Hills Pharma, LLC, Agenus, Inc., Alkermes, Inc., AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Exelixis, Inc. - Commercial, Fluidigm Corporation, Gamida Cell, IsoPlexis, Janssen Pharmaceutical Research & Development, LLC, Incyte Corporation, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., NanoString Technologies, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sensei Biotherapies, Inc. (as of Nov. 1, 2021)

    Program Schedule


    Schedule At-a-Glance

    Wednesday, Nov. 10
    Pre-Conference Programs

    World Immunotherapy Council's 4th Young Investigator Symposium

    The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

    Thursday, Nov. 11
    Pre-Conference Programs

    Primer on Tumor Immunology and Cancer Immunotherapy™

    Immuno-Resistance and Sequencing Symposium

    Meet-the-Expert Lunch

    Grant Writing Workshop

    Friday, Nov. 12
    Annual Meeting

    36th Annual Meeting

    Saturday, Nov. 13
    Annual Meeting

    36th Annual Meeting

    Sunday, Nov. 14
    Annual Meeting

    36th Annual Meeting

    SITC Related Resources

    SITC offers a variety of resources about immunology and immunotherapy. Explore the pages below to learn more.